Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mediator complex subunit 12-like protein (MED12L) is a subunit of the Mediator kinase module, a multi-protein complex that acts as a coactivator for RNA polymerase II-dependent transcription in almost all eukaryotes[1][2][5]. As part of this module, MED12L helps relay signals from gene-specific regulators to the basal transcription machinery and is important for the regulation of gene expression during development, especially in the nervous system[1][5]. Genetic variants causing loss of function in MED12L are associated with intellectual disability, developmental delay, and speech impairment, sometimes accompanied by behavioral abnormalities and mild facial differences[1]. MED12L is highly expressed in the brain and is predicted to share domain homology with MED12, including roles in Wnt/beta-catenin pathway activation[1]. While key to fundamental transcriptional processes, MED12L is not currently considered a therapeutic target or site of known drug interaction[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mediator complex subunit 12-like protein (MED12L).